Your browser doesn't support javascript.
loading
Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik, Alexandra S; Klein, David E; Liedke, Maryana; Kaunzner, Ulrike W; Nealon, Nancy M; Gauthier, Susan A; Vartanian, Timothy; Perumal, Jai S.
Afiliação
  • Kocsik AS; Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.
  • Klein DE; Touro College of Osteopathic Medicine, 60 Prospect Avenue, Middletown, NY, 10940, USA.
  • Liedke M; Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.
  • Kaunzner UW; Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.
  • Nealon NM; Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.
  • Gauthier SA; Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.
  • Vartanian T; Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.
  • Perumal JS; Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA. jsp9007@med.cornell.edu.
J Neurol ; 265(5): 1226-1229, 2018 May.
Article em En | MEDLINE | ID: mdl-29666985
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Fatores Imunológicos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: J Neurol Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Fatores Imunológicos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: J Neurol Ano de publicação: 2018 Tipo de documento: Article